阿托伐他汀联合微创置管引流术与单行纯微创置管引流术治疗慢性硬膜下血肿患者的优劣差异

目的 探讨阿托伐他汀联合经锥颅微创置管引流术与单行纯经锥颅微创置管引流术治疗慢性硬膜下血肿患者(CSDH)的临床疗效差异。方法 选取我院2016年1月至2018年12月CSDH患者62例,随机分为对照组(30例)和观察组(32例)；对照组予以经锥颅微创置管引流术治疗；观察组予以微创置管引流术+阿托伐他汀治疗。观察两组临床疗效,神经功能缺损(CSS)评分、日常生活活动能力量表(ADL)评分及并发症、疾病复发情况。结果 治疗后,观察组临床疗效明显高于对照组(P<0.05)；观察组CSS评分低于对照组(P<0.05),ADL评分明显高于对照组(P<0.05)；观察组总并发症发生率和复发率明显低于对照组(P<0.05)。结论 阿托伐他汀联合经锥颅微创置管引流术治疗CSDH,清除颅内血肿,改善患者神经功能,能达到更好的临床疗效。

The difference between atorvastatin combined with minimally invasive catheter drainage and single minimally invasive catheter drainage in the treatment of chronic subdural hematoma patients

objective to investigate the difference of clinical efficacy between atorvastatin combined with minimally invasive transcranial and single minimally invasive transcranial tube drainage in the treatment of chronic subdural hematoma (CSDH). Methods 62 patients with CSDH in our hospital from January 2016 to December 2018 were selected and randomly divided into control group (30 cases) and observation group (32 cases). The control group was treated with minimally invasive catheter drainage through cranial cone. The observation group was treated with minimally invasive catheter drainage plus atorvastatin. The clinical efficacy, CSS score, ADL score, complications and disease recurrence of the two groups were observed. Results after treatment, the clinical efficacy of the observation group was significantly higher than that of the control group (P<0.05). The CSS score of the observation group was lower than that of the control group (P<0.05), and the ADL score was significantly higher than that of the control group (P<0.05). The total complication rate and recurrence rate in the observation group were significantly lower than those in the control group (P<0.05). Conclusion the treatment of CSDH with atorvastatin combined with minimally invasive transcranial tube drainage can remove intracranial hematoma and improve the neurological function of patients, achieving better clinical efficacy.